Abstract: Technologies for adaptive network packet egress scheduling include a switch configured to configure an eligibility table for a plurality of ports of the switch, wherein the eligibility table includes a plurality of rounds. The switch is further configured to retrieve an eligible mask corresponding to a round of a plurality of rounds of the eligibility table presently being scheduled and determine a ready mask that indicates a ready status of each port. The switch is further configured to determine, for each port, whether the eligible status and the ready status indicate that port is both eligible and ready, and schedule, in response to a determination that at least one port has been determined to be both eligible and ready, each of the at least one port that has been determined to be both eligible and ready. Additional embodiments are described herein.

Abstract: Technologies for adaptive network packet egress scheduling include a switch configured to configure an eligibility table for a plurality of ports of the switch, wherein the eligibility table includes a plurality of rounds. The switch is further configured to retrieve an eligible mask corresponding to a round of a plurality of rounds of the eligibility table presently being scheduled and determine a ready mask that indicates a ready status of each port. The switch is further configured to determine, for each port, whether the eligible status and the ready status indicate that port is both eligible and ready, and schedule, in response to a determination that at least one port has been determined to be both eligible and ready, each of the at least one port that has been determined to be both eligible and ready. Additional embodiments are described herein.

Abstract: A system for detecting dehydration, hemorrhaging, and increases in blood volume comprising monitors the time difference between the arrival of the primary left ventricular ejection pulse (pulse T1) and the arrival of the iliac reflection (pulse T3) to determine an arterial pulse parameter which is the time difference between T1 T3. Changes in T3 minus T1 are indicative of something happening to blood volume. If the T1?3 value goes up and the patient is on an infusion system, it can be an indication of having too much fluid pumped and if T1?3 is lower than it should be for an individual, they are either dehydrated (which can result in decreases in blood volume), they are hemorrhaging, or they have hemorrhaged.

Abstract: A securitization structure for raising capital, where notes issued under the structure are backed by a plurality of real property assets. The structure includes one or more asset holders that hold a plurality of real property assets. The structure also includes one or more issuers that issue notes to noteholders, wherein the notes are supported by the real property assets including cash flows therefrom, but where the noteholders do not have the benefit of a material amount of security interests in the plurality of real property assets, wherein at least one title insurance policy exists for the benefit of noteholders with respect to one or more of the plurality of real property assets that are not subject to a security interest for the benefit of the noteholders, and wherein the noteholders have the benefit of a security interest in the equity interests of the one or more asset holders that are pledged as security for the notes.

Abstract: The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1 is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II): —N(R9)—C(?X)—(Y)n—R10, wherein R9 hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

Abstract: The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1 is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II): —N(R9)—C(═X)—(Y)n—R10, wherein R9 hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

Abstract: A personal financial management program is disclosed incorporating means of implementing, coordinating, supervising, analyzing and reporting upon investments in an array of asset accounts and credit facilities within a client account. Through a mathematical programming function the client specifies his financial objectives, his risk preference, forecast of economic and financial variables, and budgetary constraints. The mathematical programming function suggests to the client a portfolio of investment and credit facilities to best realize his financial objectives over a defined time horizon. In the preferred embodiment the central structural element of the financial account is a mortgage secured by the client's home and one or more asset accounts. Client funds that would normally be used to amortize the mortgage may be alternatively used to increase the value of a designated asset account.